KLOW is a fixed four-peptide blend in one 80mg vial: GHK-Cu 50mg, BPC-157 10mg, TB-500 10mg, and KPV 10mg (a 5:1:1:1 mass ratio).

No validated human dose exists for the blend. In research practice the 80mg vial is reconstituted with bacteriostatic water and administered subcutaneously. Because the ratio is fixed, every draw delivers all four peptides proportionally — GHK-Cu is 62.5% of any draw. Use the reconstitution calculator to see the exact mg of each peptide per draw.

How do you reconstitute an 80mg KLOW vial?

Add bacteriostatic water to the lyophilized 80mg vial. For example, 2 mL of BAC water gives a total-blend concentration of 40 mg/mL; a 5-unit (0.05 mL) draw then delivers roughly GHK-Cu 1.25 mg, BPC-157 250 mcg, TB-500 250 mcg, and KPV 250 mcg.

Home › Catalog › KLOW

KLOW Blend Protocol

KLOW is a fixed four-peptide research blend — GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg in a single 80 mg vial — combining copper-mediated regeneration, tissue repair, cell-migration, and anti-inflammatory pathways studied individually across its four components.

80 mg vial · 5:1:1:1 ratio Subcutaneous Research Use Only · Not FDA-approved

Research Use Only. KLOW and its components are sold for laboratory research only — not for human or animal consumption. There are no clinical trials of the four-peptide blend and no validated human dose. Everything below reflects the published literature on the individual components and common research reconstitution practice. Not medical advice. Consult a licensed healthcare provider before any use — especially if pregnant or nursing, managing a medical condition, or taking other medications.

1What's in the vial

KLOW is a fixed blend — the four peptides are lyophilized together in one vial, so you cannot dose them separately. The mass ratio is always 50 : 10 : 10 : 10 (GHK-Cu is 62.5% of the total).

Component	Amount	% of blend	Studied for
GHK-Cu	50 mg	62.5%	Copper-mediated regeneration, skin remodeling
BPC-157	10 mg	12.5%	Tissue repair, gut & tendon healing
TB-500	10 mg	12.5%	Cell migration, soft-tissue repair
KPV	10 mg	12.5%	Anti-inflammatory (α-MSH fragment)
Total: 80 mg per vial

2Reconstitute & dose

Because the ratio is fixed, every draw delivers all four peptides proportionally — you dose the blend, not one peptide. The calculator below shows exactly how many mg of each peptide any draw delivers. Anchor your draw to whichever component you're studying (most researchers anchor to GHK-Cu, the 62.5% majority, or to the BPC-157 / TB-500 tissue-repair range).

A few common reconstitution points for the 80 mg vial (BAC water = bacteriostatic water):

BAC water added	Concentration	A 5-unit (0.05 mL) draw delivers
1 mL	80 mg/mL	GHK-Cu 2.5 mg · BPC/TB/KPV 500 mcg each
2 mL	40 mg/mL	GHK-Cu 1.25 mg · BPC/TB/KPV 250 mcg each
4 mL	20 mg/mL	GHK-Cu 625 mcg · BPC/TB/KPV 125 mcg each

These are arithmetic examples of what a draw delivers at a given reconstitution — not dose recommendations. Use the calculator to model your own vial and draw.

3Administration & storage

Route. In research practice KLOW is administered subcutaneously with a U-100 insulin syringe. (GHK-Cu on its own is also studied topically, but the blend is reconstituted and injected.)

Storage. Store the lyophilized vial cold and protected from light; once reconstituted with bacteriostatic water, refrigerate (2–8 °C) and use within the BAC water's preservative window. GHK-Cu is copper-blue in solution — a faint blue tint after reconstitution is expected.

4What each peptide is studied for

GHK-Cu 50 mg

Copper-binding tripeptide; the best-characterized component. Studied for skin remodeling, wound signaling, and antioxidant gene expression.

BPC-157 10 mg

Gastric pentadecapeptide studied in preclinical models for tissue, tendon, and gut-barrier repair.

TB-500 10 mg

Thymosin β4 fragment studied for actin regulation, cell migration, and soft-tissue repair.

KPV 10 mg

C-terminal α-MSH tripeptide (Lys-Pro-Val) studied for anti-inflammatory signaling.

5Evidence

No study evaluates the four-peptide blend together; the evidence base is the individual components' preclinical literature:

Pickart 2015 — GHK-Cu review (PMID 26236730)
He 2022 — BPC-157 rat/dog PK (PMID 36568636)
Sikiric 2018 — BPC-157 preclinical review (PMID 29141577)
Crockford 2010 — TB-500 / Tβ4 preclinical review (PMID 20594025)

6Regulatory & safety

None of the four components is FDA-approved. BPC-157 is on the FDA 503A Category 2 interim list; BPC-157 and TB-500 are prohibited by WADA. Human safety data for these compounds — individually and especially as a blend — is limited or absent. Research Use Only; not for human or animal use.